胶质瘤中MGMT、BRAF和EGFR的变化及其治疗的研究进展

Research Progress in Changes of MGMT,BRAF and EGFR in Gliomas and their Correlation with Treatment of Gliomas

随着分子生物学技术的发展与进步,针对胶质瘤的诊断、鉴别诊断和靶向药物治疗的分子标志物的研究取得了很大的进展。其中,根据O6-甲基鸟嘌呤-DNA-甲基转移酶(MGMT)、鼠类肉瘤滤过性毒菌致癌同源体B1(BRAF)基因和表皮生长因子受体(EGFR)研发的药物也在脑胶质瘤治疗中取得了一定的效果。不同类型的胶质瘤有着不同的发病机制,基于不同分子标志物的药物为胶质瘤患者的个体化治疗或联合治疗提供了新的研究方向。本文就胶质瘤中MGMT、BRAF和EGFR的变化及其与胶质瘤治疗的研究进展进行了综述。

With the development and progress of molecular biology techniques, the research of molecular markers for diagnosis, differential diagnosis and targeted drug therapy of gliomas has also made a great progress. The drugs developed on the base of molecular markers like 06-methylguanine-DNA methyhransferase （MGMT）, murine sarcoma viral oncogenic homolog B 1 （BRAF） gene and epidermal growth factor receptor （EGFR） also achieved some results in the treatment of glioma. Different types of gliomas have different pathogenesis, and the drugs based on different molecular markers provided a new re- search direction for individualized treatment and combination therapy of glioma patients. In this paper, the changes of EGFR, BRAF and MGMT in gliomas and the progress of glioma therapy were reviewed.